Regenxbio: Advancing its Gene Therapy Pipeline and its Rare Neurodegenerative Disease Platform with Non-Dilutive Capital


Regenxbio (RGNX) announced that it is selling a portion of its royalty rights from the net sales of Zolgensma® by Novartis to entities managed by Healthcare Royalty Management, LLC (HCR) for $200 million.

This transaction provides immediate, non-dilutive capital to Regenxbio in order continue the development of its gene therapy pipeline products and complete its internal manufacturing capabilities.

Morgan Stanley & Co. LLC served as the sole structuring agent, Covington & Burling LLP served as counsel to Regenxbio; Morgan Lewis & Bockius LLP acted as counsel to HCR.

Leave a Reply